{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-006937","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.907912+00:00","generated_at":"2026-05-16T02:34:22.845900+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Telomir reports Telomir-1 induces near-complete tumor cell death in TNBC models; iron-rescue confirms mechanism","bullets":["Near-complete tumor cell mortality in MDA-MB-468 (Basal-A/EGFR-high) TNBC cells at 72h.","Significant partial reduction in HCC70 (Basal-like) and MDA-MB-231 (Claudin-low) cells.","Supplemental iron attenuated Telomir-Zn-induced mortality, supporting iron-dependent mechanism.","Prior zebrafish xenograft showed reduced growth/metastasis; IND submission expected Q1 2026.","GLP safety studies in rats/dogs showed no adverse toxicity; IND-enabling activities ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-006937","json":"https://secwatch.observer/filing/0001493152-26-006937.json","markdown":"https://secwatch.observer/filing/0001493152-26-006937.md","text":"https://secwatch.observer/filing/0001493152-26-006937.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226006937/0001493152-26-006937-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226006937/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:34:22.845900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}